Hormoontherapie voor prostaatkanker: gevolgen voor de botgezondheid

Jorg R. Oddens; Marsha van Oostwaard

doi:10.1007/s13629-024-00422-8

Hormoontherapie voor prostaatkanker: gevolgen voor de botgezondheid

Translated title of the contribution: Hormonal treatment for prostate cancer: repercussions for bone health

Jorg R. Oddens^*
, Marsha van Oostwaard

^*Corresponding author for this work

VieCuri Medisch Centrum

Research output: Contribution to journal › Article › Professional

23 Downloads (Pure)

Abstract

The treatment of prostate cancer with androgen deprivation therapy (ADT) causes a decrease in bone density as a side effect. For prescribers of this treatment, knowledge of the prevention of osteoporosis and fracture risk is important, as well as knowledge about the indication for follow-up testing or indication for additional lifestyle measures and therapy. In this article we discuss the relationship of ADT with osteoporosis and fracture risk based on the literature and give recommendations based on the Dutch prostate cancer guideline and the recently published Dutch guideline on osteoporosis and fracture prevention.

Translated title of the contribution	Hormonal treatment for prostate cancer: repercussions for bone health
Original language	Dutch
Pages (from-to)	58-62
Number of pages	5
Journal	Tijdschrift voor urologie
Volume	14
Issue number	2-3
DOIs	https://doi.org/10.1007/s13629-024-00422-8
Publication status	Published - 1 Mar 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Androgen deprivation therapy
Fracture risk
Osteoporosis
Prostate cancer

Access to Document

10.1007/s13629-024-00422-8

Hormoontherapie-voor-prostaatkanker.pdfFinal published version, 248 KBLicence: CC BY

Cite this

@article{db3565c961b24e9698296003e99c906a,

title = "Hormoontherapie voor prostaatkanker: gevolgen voor de botgezondheid",

abstract = "The treatment of prostate cancer with androgen deprivation therapy (ADT) causes a decrease in bone density as a side effect. For prescribers of this treatment, knowledge of the prevention of osteoporosis and fracture risk is important, as well as knowledge about the indication for follow-up testing or indication for additional lifestyle measures and therapy. In this article we discuss the relationship of ADT with osteoporosis and fracture risk based on the literature and give recommendations based on the Dutch prostate cancer guideline and the recently published Dutch guideline on osteoporosis and fracture prevention.",

keywords = "Androgen deprivation therapy, Fracture risk, Osteoporosis, Prostate cancer",

author = "Oddens, \{Jorg R.\} and \{van Oostwaard\}, Marsha",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = mar,

day = "1",

doi = "10.1007/s13629-024-00422-8",

language = "Dutch",

volume = "14",

pages = "58--62",

journal = "Tijdschrift voor urologie",

issn = "2211-3037",

publisher = "Springer Science + Business Media",

number = "2-3",

}

TY - JOUR

T1 - Hormoontherapie voor prostaatkanker

T2 - gevolgen voor de botgezondheid

AU - Oddens, Jorg R.

AU - van Oostwaard, Marsha

PY - 2024/3/1

Y1 - 2024/3/1

N2 - The treatment of prostate cancer with androgen deprivation therapy (ADT) causes a decrease in bone density as a side effect. For prescribers of this treatment, knowledge of the prevention of osteoporosis and fracture risk is important, as well as knowledge about the indication for follow-up testing or indication for additional lifestyle measures and therapy. In this article we discuss the relationship of ADT with osteoporosis and fracture risk based on the literature and give recommendations based on the Dutch prostate cancer guideline and the recently published Dutch guideline on osteoporosis and fracture prevention.

AB - The treatment of prostate cancer with androgen deprivation therapy (ADT) causes a decrease in bone density as a side effect. For prescribers of this treatment, knowledge of the prevention of osteoporosis and fracture risk is important, as well as knowledge about the indication for follow-up testing or indication for additional lifestyle measures and therapy. In this article we discuss the relationship of ADT with osteoporosis and fracture risk based on the literature and give recommendations based on the Dutch prostate cancer guideline and the recently published Dutch guideline on osteoporosis and fracture prevention.

KW - Androgen deprivation therapy

KW - Fracture risk

KW - Osteoporosis

KW - Prostate cancer

UR - https://www.scopus.com/pages/publications/85186400442

U2 - 10.1007/s13629-024-00422-8

DO - 10.1007/s13629-024-00422-8

M3 - Article

SN - 2211-3037

VL - 14

SP - 58

EP - 62

JO - Tijdschrift voor urologie

JF - Tijdschrift voor urologie

IS - 2-3

ER -

Hormoontherapie voor prostaatkanker: gevolgen voor de botgezondheid

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this